<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2392">
  <stage>Registered</stage>
  <submitdate>8/06/2009</submitdate>
  <approvaldate>8/06/2009</approvaldate>
  <nctid>NCT00917306</nctid>
  <trial_identification>
    <studytitle>A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)</studytitle>
    <scientifictitle>A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-020</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Actinic Keratosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005 Gel

Experimental: PEP005 gel - PEP005 gel, 0.05% administered once daily for 2 consecutive days


Treatment: drugs: PEP005 Gel
0.05% two day treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety (Incidence of treatment related AEs, local skin reactions and pigmentation and scarring)</outcome>
      <timepoint>57 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy (complete and partial clearance of AK lesions)</outcome>
      <timepoint>57 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient is male or female and at least 18 years of age.

          -  Female patient must be of either:

               -  Non-childbearing potential, post-menopausal, or there is a confirmed clinical
                  history of sterility (e.g., the patient is without a uterus)

               -  Childbearing potential, provided there are negative urine pregnancy test results
                  prior to study treatment, to rule out pregnancy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Cosmetic or therapeutic procedures within two weeks and within 2 cm of the selected
             treatment area.

          -  Treatment with immunomodulators, interferon/ interferon inducers or systemic
             medications that suppress the immune system within 4 weeks.

          -  Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks
             and 2 cm of the selected treatment area.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>102</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Dematology on Ward - Adelaide</hospital>
    <hospital>Dermatology Institute of Victoria - Melbourne</hospital>
    <hospital>St John of God Dermatology - Subiaco</hospital>
    <postcode>5006 - Adelaide</postcode>
    <postcode>3141 - Melbourne</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>TKL Research, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The open label study is designed to assess the safety and efficacy of 0.05% PEP005 Gel when
      applied to an area of skin containing 4-8 AK lesions on non-head locations.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00917306</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Eugene Bauer, MD</name>
      <address>Chief Medical Officer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>